meREWARDS allows you to get coupons and earn cash when you answer surveys, dinner and buy with our partners
LONDON: The treatment of critically ill patients with COVID-19 with corticosteroids reduces the death threat by 20%, a seven-trial investigation of foreigners discovered on Wednesday, September 2, leading the World Health Organization to update its recommendations on remedies.
Research, which included knowledge of separate trials on hydrocortisone, dexamethasone and low-dose methylprednisolone, found that steroids increased survival rates for COVID-19 patients who were sufficient to receive intensive care in the hospital.
“This equates to about 68% of patients (the sickest coVID-19) who after corticosteroid treatment, compared to about 60% who survive in the absence of corticosteroids,” the researchers said in a statement.
WHO Head of Clinical Care Janet Diaz said the firm had updated its recommendation to include a “strong recommendation” for steroid use in patients with severe and critical COVID-19.
“Evidence shows that if you administer corticosteroidsArray . . . (there are) 87 less consistent deaths with 1,000 patients,” he once said on WHO social media. “These are sArray . . . kept. “
Jonathan Sterne, professor of medical statistics and epidemiology at the British University of Bristol who worked on the analysis, said the trials, conducted through researchers in Britain, Brazil, Canada, China, France, Spain and the United States, conveyed a coherent message. at all times, appearing that the drugs were in the sickest patients. Arrange regardless of age or gender or how long patients have been sick.
The findings, published in the Journal of the American Medical Association, were hailed as a major breakthrough and announced in June, when dexamethasone became the first drug capable of reducing mortality rates in critically critical COVID-19 patients.
Since then, dexamethasone has been widely used in extensive care sets for the treatment of COVID-19 patients in some countries.
Martin Landray, professor of medicine and epidemiology at Oxford University who worked on the dexamethasone trial, which is a key component of the grouped research published Wednesday, said the findings mean that doctors in hospitals around the world can safely switch to drug use. saves lives.
Who’s updated guidelines, published on its online page on Wednesday night, established that corticosteroids deserve to be used only in the remedies of the sickest patients of COVID-19, not in non-serious cases, because “the remedy did not bring with it anyone gets advantages (in milder cases) and may even be harmful. “
The UN fitness firm also suggested that countries have sufficient corticosteroid reserves, “without exceeding the higher stocks that can save them access to other countries. “
Researchers said the benefits of obtaining were demonstrated regardless of the fact that patients were ventilated at the time they started treatment.
Download our app or subscribe to our Telegram channel to receive updates to the COVID-19 outbreak: https://cna. asia/telegram